AstraZeneca tops quarterly estimates buoyed by cancer drugs
Source: Reuters
Company raises full year adjusted EPS forecastSales of broader oncology product portfolio up 24%Shares rise nearly 2% in early tradeNov 10 (Reuters) - AstraZeneca (AZN.L) on Thursday raised its full-year adjusted earnings forecast after third-quarter profit and revenue topped analysts' expectations, helped by sales of its key cancer drugs.Oncology is AstraZeneca's biggest disease area, with cancer drugs…
This is aggregated or syndicated coverage. Reporting and media belong to the original publisher.
Read the original source at Reuters